Specialist in cystic fibrosis medication plans to raise growth potential with expanding portfolio

Nasdaq-listed Vertex Pharmaceuticals is a global biotechnology company that innovates and creates transformative medicines for people with serious diseases. The company’s area of expertise lies in cystic fibrosis (CF), a rare life-threatening genetic disease, of which Vertex has multiple approved medicines along with several ongoing clinical and research programmes. Vertex derives all of its revenue from the CF segment as the rest of its research are only in the pipeline — either in Phase 2 or prior.

Its pipeline excluding CF consists of two parts: The first is investigational small molecule medicines in other serious diseases covering the areas of pain, protein deficiency and kidney diseases. The other is genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, muscular dystrophy and type-1 diabetes.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook